F8 and hemophilia A: This study demonstrates that glycopegylated EHL FVIII and EHL FIX prophylaxis significantly improve clinical outcomes in patients with hemophilia A and B. The substantial reductions in ABRs, along with enhanced joint health and functional independence, highlight the efficacy and safety of these therapies in a resource-constrained setting.